Eagle Pharmaceuticals (EGRX) Tops Q2 EPS by 4c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Eagle Pharmaceuticals (EGRX) Tops Q2 EPS by 4c

Eagle Pharmaceuticals, Inc. Reports Second Quarter 2015 Results

August 11, 2015 6:50 AM EDT

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)-- Eagle Pharmaceuticals, Inc. (Eagle or the Company) (Nasdaq: EGRX) today announced its financial results for the three- and six-month periods ended June 30, 2015. Highlights of and subsequent to the second quarter of 2015 include:

The U.S. Food and Drug Administration (FDA) accepted for filing the New Drug Application (NDA) for Eagles bendamustine hydrochloride (HCl) rapid infusion product (the rapid infusion product) for the treatment of patients with chronic lymphocytic leukemia (CLL) and patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of... More